Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain D Baron

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 11, 2005
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitusOrville G Kolterman, Dennis D Kim, Larry Shen, et al.
Diabetes Care|July 29, 2003
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetesMark S Fineman, Thomas A Bicsak, Larry Z Shen, et al.
Endocrinology|December 25, 2004
Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weightBronislava R Gedulin, Svetlana E Nikoulina, Pamela A Smith, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2008
Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studiesJonathan D Roth, Barbara L Roland, Rebecca L Cole, et al.
Endocrinology|August 2, 2008
Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanismsJames L Trevaskis, Todd Coffey, Rebecca Cole, et al.
The Journal of Clinical Endocrinology and Metabolism|July 5, 2003
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetesOrville G Kolterman, John B Buse, Mark S Fineman, et al.
The Journal of Sexual Medicine|December 2, 2008
The novel antioxidant, AC3056 (2,6-di-t-butyl-4-((dimethyl-4-methoxyphenylsilyl)methyloxy)phenol), reverses erectile dysfunction in diabetic rats and improves NO-mediated responses in penile tissue from diabetic menJavier Angulo, Concepción Peiró, Pedro Cuevas, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 11, 2005
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitusOrville G Kolterman, Dennis D Kim, Larry Shen, et al.
Diabetes Care|July 29, 2003
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetesMark S Fineman, Thomas A Bicsak, Larry Z Shen, et al.
Endocrinology|December 25, 2004
Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weightBronislava R Gedulin, Svetlana E Nikoulina, Pamela A Smith, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2008
Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studiesJonathan D Roth, Barbara L Roland, Rebecca L Cole, et al.
Endocrinology|August 2, 2008
Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanismsJames L Trevaskis, Todd Coffey, Rebecca Cole, et al.
The Journal of Clinical Endocrinology and Metabolism|July 5, 2003
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetesOrville G Kolterman, John B Buse, Mark S Fineman, et al.
The Journal of Sexual Medicine|December 2, 2008
The novel antioxidant, AC3056 (2,6-di-t-butyl-4-((dimethyl-4-methoxyphenylsilyl)methyloxy)phenol), reverses erectile dysfunction in diabetic rats and improves NO-mediated responses in penile tissue from diabetic menJavier Angulo, Concepción Peiró, Pedro Cuevas, et al.
Pageof 3